Electric vehicles displaced 200 million barrels of oil worth $20 billion worldwide in six months, analysis finds
A new analysis by energy think tank Ember, reported October 22, found that electric vehicles displaced an estimated 200 million barrels of crude oil, worth roughly $20 billion, across 56 countries between March and August 2026. Those countries account for more than 90 percent of global EV sales, with China seeing the largest savings at about $14 billion thanks to its roughly 44 million EVs, while EU member states collectively saved around $3.1 billion, led by Germany and France. Denmark topped Europe on a per-capita basis, with its EV fleet now displacing an estimated 13 percent of the country's annualized 2025 oil consumption, underscoring how quickly electrification is cutting into fossil fuel demand even as global oil markets remain volatile.
Read more →Electric vehicles displaced 200 million barrels of oil worth $20 billion worldwide in six months, analysis finds
A new analysis by energy think tank Ember, reported October 22, found that electric vehicles displaced an estimated 200 million barrels of crude oil, worth roughly $20 billion, across 56 countries between March and August 2026. Those countries account for more than 90 percent of global EV sales, with China seeing the largest savings at about $14 billion thanks to its roughly 44 million EVs, while EU member states collectively saved around $3.1 billion, led by Germany and France. Denmark topped Europe on a per-capita basis, with its EV fleet now displacing an estimated 13 percent of the country's annualized 2025 oil consumption, underscoring how quickly electrification is cutting into fossil fuel demand even as global oil markets remain volatile.
Kazakhstan launches platform seeking €18 billion to fund its shift to renewable energy
Kazakhstan unveiled its QaJET just energy transition platform on October 21, backed by the European Bank for Reconstruction and Development, with the aim of mobilising roughly $20 billion (about €18 billion) in clean energy investment. Around half of that funding is earmarked to support 10 gigawatts of new renewable energy capacity by 2035, in a country where fossil fuels still supply about 85 percent of electricity. The platform already includes a 1-gigawatt wind farm being developed by TotalEnergies and Kazakh partners, due to come online in 2028, with the EBRD crediting regulatory reforms, competitive auctions and long-term power purchase agreements for drawing in investors despite remaining grid capacity constraints.
Read more →Kazakhstan launches platform seeking €18 billion to fund its shift to renewable energy
Kazakhstan unveiled its QaJET just energy transition platform on October 21, backed by the European Bank for Reconstruction and Development, with the aim of mobilising roughly $20 billion (about €18 billion) in clean energy investment. Around half of that funding is earmarked to support 10 gigawatts of new renewable energy capacity by 2035, in a country where fossil fuels still supply about 85 percent of electricity. The platform already includes a 1-gigawatt wind farm being developed by TotalEnergies and Kazakh partners, due to come online in 2028, with the EBRD crediting regulatory reforms, competitive auctions and long-term power purchase agreements for drawing in investors despite remaining grid capacity constraints.
Immune response to experimental cancer vaccine linked to longer survival in colorectal cancer trial
Biotech company Enterome reported final Phase 1/2 data on October 23 showing that patients with colorectal cancer who developed an early expansion of CD8 T-cells after treatment with its OncoMimics immunotherapy EO4010 lived significantly longer than those who did not show that immune response. The findings strengthen the case that the treatment, which trains the immune system to attack tumour cells using bacterial mimics of cancer antigens, could offer a meaningful survival benefit for a cancer that remains one of the leading causes of cancer death worldwide. The results point toward T-cell expansion as a potential biomarker for identifying which patients are most likely to benefit, informing the design of larger trials to come.
Read more →Immune response to experimental cancer vaccine linked to longer survival in colorectal cancer trial
Biotech company Enterome reported final Phase 1/2 data on October 23 showing that patients with colorectal cancer who developed an early expansion of CD8 T-cells after treatment with its OncoMimics immunotherapy EO4010 lived significantly longer than those who did not show that immune response. The findings strengthen the case that the treatment, which trains the immune system to attack tumour cells using bacterial mimics of cancer antigens, could offer a meaningful survival benefit for a cancer that remains one of the leading causes of cancer death worldwide. The results point toward T-cell expansion as a potential biomarker for identifying which patients are most likely to benefit, informing the design of larger trials to come.
FDA converts pembrolizumab's accelerated approval to full approval for high-mutation-burden solid tumors
The US Food and Drug Administration has converted its earlier accelerated approval of the immunotherapy drug pembrolizumab into a traditional, full approval for adults and children with unresectable or metastatic tumor-mutational-burden-high solid tumors, setting the qualifying threshold at 13 or more mutations per megabase, according to reporting on October 22. The shift to full approval reflects confirmed clinical benefit from follow-up data and removes the conditional status that had applied since the drug's earlier accelerated clearance, giving oncologists and patients more certainty about its long-term availability as a treatment option for this group of hard-to-treat cancers defined by their high mutation load rather than their site of origin.
Read more →FDA converts pembrolizumab's accelerated approval to full approval for high-mutation-burden solid tumors
The US Food and Drug Administration has converted its earlier accelerated approval of the immunotherapy drug pembrolizumab into a traditional, full approval for adults and children with unresectable or metastatic tumor-mutational-burden-high solid tumors, setting the qualifying threshold at 13 or more mutations per megabase, according to reporting on October 22. The shift to full approval reflects confirmed clinical benefit from follow-up data and removes the conditional status that had applied since the drug's earlier accelerated clearance, giving oncologists and patients more certainty about its long-term availability as a treatment option for this group of hard-to-treat cancers defined by their high mutation load rather than their site of origin.